Matrix-Mediated Delivery of Silver Nanoparticles for Prevention of Staphylococcus aureus and Pseudomonas aeruginosa Biofilm Formation in Chronic Rhinosinusitis
- PMID: 37896186
- PMCID: PMC10610389
- DOI: 10.3390/pharmaceutics15102426
Matrix-Mediated Delivery of Silver Nanoparticles for Prevention of Staphylococcus aureus and Pseudomonas aeruginosa Biofilm Formation in Chronic Rhinosinusitis
Abstract
Chronic rhinosinusitis (CRS) is a chronic health condition affecting the sinonasal cavity. CRS-associated mucosal inflammation leads to sinonasal epithelial cell death and epithelial cell barrier disruption, which may result in recurrent bacterial infections and biofilm formation. For patients who fail medical management and elect endoscopic sinus surgery for disease control, bacterial biofilm formation is particularly detrimental, as it reduces the efficacy of surgical intervention. Effective treatments that prevent biofilm formation in post-operative patients in CRS are currently limited. To address this unmet need, we report the controlled release of silver nanoparticles (AgNps) with silk-elastinlike protein-based polymers (SELPs) to prevent bacterial biofilm formation in CRS. This polymeric network is liquid at room temperature and forms a hydrogel at body temperature, and is hence, capable of conforming to the sinonasal cavity upon administration. SELP hydrogels demonstrated sustained AgNp and silver ion release for the studied period of three days, potent in vitro antibacterial activity against Pseudomonas aeruginosa (**** p < 0.0001) and Staphylococcus aureus (**** p < 0.0001), two of the most commonly virulent bacterial strains observed in patients with post-operative CRS, and high cytocompatibility with human nasal epithelial cells. Antibacterial controlled release platform shows promise for treating patients suffering from prolonged sinonasal cavity infections due to biofilms.
Keywords: SELPs; biofilm; chronic rhinosinusitis; in situ gel; silver nanoparticle; sustained release.
Conflict of interest statement
The authors declare no conflict of interest.
Figures









Similar articles
-
Silver nanoparticles as a bioadjuvant of antibiotics against biofilm-mediated infections with methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in chronic rhinosinusitis patients.Pathology. 2022 Jun;54(4):453-459. doi: 10.1016/j.pathol.2021.08.014. Epub 2021 Nov 26. Pathology. 2022. PMID: 34844745
-
Ultrasmall AgNP-Impregnated Biocompatible Hydrogel with Highly Effective Biofilm Elimination Properties.ACS Appl Mater Interfaces. 2020 Sep 16;12(37):41011-41025. doi: 10.1021/acsami.0c09414. Epub 2020 Sep 3. ACS Appl Mater Interfaces. 2020. PMID: 32840353
-
The mechanisms of biofilm antibiotic resistance in chronic rhinosinusitis: A review.Medicine (Baltimore). 2022 Dec 9;101(49):e32168. doi: 10.1097/MD.0000000000032168. Medicine (Baltimore). 2022. PMID: 36626427 Free PMC article. Review.
-
Sinonasal Stent Coated with Slow-Release Varnish of Chlorhexidine Has Sustained Protection against Bacterial Biofilm Growth in the Sinonasal Cavity: An In Vitro Study.Pharmaceutics. 2021 Oct 25;13(11):1783. doi: 10.3390/pharmaceutics13111783. Pharmaceutics. 2021. PMID: 34834197 Free PMC article.
-
Topical Antibiofilm Agents With Potential Utility in the Treatment of Chronic Rhinosinusitis: A Narrative Review.Front Pharmacol. 2022 Jun 13;13:840323. doi: 10.3389/fphar.2022.840323. eCollection 2022. Front Pharmacol. 2022. PMID: 35770097 Free PMC article. Review.
Cited by
-
Transdermal delivery of ultradeformable cationic liposomes complexed with miR211-5p (UCL-211) stabilizes BRAFV600E+ melanocytic nevi.J Control Release. 2025 May 10;381:113586. doi: 10.1016/j.jconrel.2025.113586. Epub 2025 Mar 1. J Control Release. 2025. PMID: 40032011
-
Transdermal Delivery of Ultradeformable Cationic Liposomes Complexed with miR211-5p (UCL-211) Stabilizes BRAFV600E+ Melanocytic Nevi.bioRxiv [Preprint]. 2024 Oct 21:2024.10.17.618694. doi: 10.1101/2024.10.17.618694. bioRxiv. 2024. Update in: J Control Release. 2025 May 10;381:113586. doi: 10.1016/j.jconrel.2025.113586. PMID: 39484595 Free PMC article. Updated. Preprint.
-
Nanotechnology-Based Therapeutics for Airway Inflammatory Diseases.Clin Rev Allergy Immunol. 2025 Feb 10;68(1):12. doi: 10.1007/s12016-024-09019-w. Clin Rev Allergy Immunol. 2025. PMID: 39928241 Free PMC article. Review.
References
-
- Kaper N.M., Aarts M.C.J., Stokroos R.J., van der Heijden G.J.M.G. Healthcare utilisation, follow-up of guidelines and practice variation on rhinosinusitis in adults: A healthcare reimbursement claims study in The Netherlands. Clin. Otolaryngol. 2020;45:159–166. doi: 10.1111/coa.13453. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous